Spinraza treatment may help restore lipid balance to the cerebrospinal fluid (CSF) of children with SMA, according to a small ...
Currently, treatments for SMA have improved survival and helped ... compared to its main rival – Biogen's oligonucleotide Spinraza (nusinersen) – which has to be administered by injection ...
Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...
Learn more about whether Exact Sciences Corporation or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the ...
The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary ...
Columnist Helen Baldwin shares how her family joined the rare disease community after the diagnosis of her late son, Jeffrey, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results